GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.

Getting a drug from initial target discovery to U.S. regulatory approval takes between 10 and 15 years on average. Most of ...

OpenAI has unveiled GPT‑Rosalind, a new AI model focused on life sciences research. Named after Rosalind Franklin, the model ...

OpenAI have announced the early release of its new AI-powered life sciences application GPT-Rosalind to specific life science groups.

Rosalind, a biological language model for target discovery and genomics. Currently only available for US corporate customers.

Tempo's Zones Heighten Privacy Scrutiny Across Crypto Networks. Tempo is rolling out a new feature called Zones, a ...

Introduction: The New Frontier of Cyber Risk in Healthcare While hospitals and clinics have long guarded patient data against traditional ...

Image courtesy by QUE.com The New Era of NFL Draft Preparation with AI-Powered Strategies In today’s fast-paced sports ...

Efforts to improve cancer imaging technologies are crucial for diagnosing and treating the disease effectively. This transition from experimental to clinical use requires bridging the gap between ...